Trigeminal Autonomic Cephalgias (TACs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Trigeminal
Autonomic Cephalgias (TACs) Market Outlook
Thelansis’s “Trigeminal Autonomic
Cephalgias (TACs) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2025 To 2035” covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Trigeminal Autonomic Cephalgias (TACs) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
Trigeminal
Autonomic Cephalgias (TACs) Overview
Trigeminal
autonomic cephalgias (TACs) are a distinct group of primary headache disorders
characterised by strictly unilateral, severe trigeminal distribution pain
invariably accompanied by ipsilateral cranial autonomic features — lacrimation,
conjunctival injection, rhinorrhoea, ptosis, and eyelid oedema — reflecting
activation of the trigeminovascular system and parasympathetic outflow via the
sphenopalatine ganglion. The TAC spectrum encompasses cluster headache — the
most prevalent and severe form — paroxysmal hemicrania, short-lasting
unilateral neuralgiform headache attacks with conjunctival injection and
tearing (SUNCT) and cranial autonomic features (SUNA), and hemicrania continua,
each distinguished by attack duration, frequency, and critically, differential
therapeutic responsiveness. Cluster headache presents with excruciating
periorbital or temporal attacks lasting 15-180 minutes, occurring in episodic
or chronic patterns, with high-flow oxygen and subcutaneous sumatriptan as
gold-standard acute therapies and verapamil as first-line prophylaxis;
galcanezumab demonstrated efficacy in episodic cluster headache prevention.
Paroxysmal hemicrania and hemicrania continua exhibit absolute, diagnostically
pathognomonic responses to indomethacin. SUNCT and SUNA respond preferentially
to lamotrigine. Secondary TAC mimics — pituitary adenoma, cavernous sinus
pathology — mandate neuroimaging exclusion. Emerging neuromodulatory approaches
including sphenopalatine ganglion stimulation offer options in refractory cluster
headache. Prognosis varies with TAC subtype; accurate diagnosis,
subtype-specific management, and multidisciplinary headache specialist
involvement are indispensable to optimising patient outcomes and quality of
life.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and
China)
Insights driven by robust research, including:
- In-depth
interviews with leading KOLs and payers
- Physician
surveys
- RWE analysis
for claims and EHR datasets
- Secondary
research (e.g., peer-reviewed journal articles, third-party research
databases)
Deliverables format and updates*:
- Detailed Report
(PDF)
- Market Forecast
Model (MS Excel-based automated dashboard)
- Epidemiology
(MS Excel; interactive tool)
- Executive
Insights (PowerPoint presentation)
- Others: regular
updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent
updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market
forecast (2025–2035)
- Bottom-up
patient-based market forecasts validated through the top-down sales
methodology
- Covers
clinically and commercially-relevant patient populations/ line of
therapies
- Annualized
drug-level sales and patient share projections
- Utilizes our
proprietary Epilansis and Analog tool (e.g., drug uptake and erosion)
datasets and conjoint analysis approach
- Detailed
methodology/sources & assumptions
- Graphical and
tabular outputs
- Users can
customize the model based on requirements
Key business questions answered:
- How can drug
development and lifecycle management strategies be optimized across G8
markets (US, EU5, Japan, and China)?
- How large is
the patient population in terms of incidence, prevalence, segments, and
those receiving drug treatments?
- What is the
10-year market outlook for sales and patient share?
- Which events
will have the greatest impact on the market’s trajectory?
- What insights
do interviewed experts provide on current and emerging treatments?
- Which pipeline
products show the most promise, and what is their potential for launch and
future positioning?
- What are the
key unmet needs and KOL expectations for target profiles?
- What key
regulatory and payer requirements must be met to secure drug approval and
favorable market access?
- and more…
Comments
Post a Comment